5 results for "Meta-analysis: What did research on LSD find in February 2026?"

LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial

Progress in Neuro-psychopharmacology and Biological Psychiatry February 18, 2026 Dimitri Henriques Daldegan-Bueno, C Donegan, Rachael Sumner et al. 1 citation

Results suggest short-term improvements in mood following microdosed LSD in people with depression, warranting confirmation in controlled trials. It provides the pharmacokinetic parameters of 8 μg of LSD in a sample of people with depression and indicates no tolerance or sensitisation to repeated microdoses of LSD, despite incremental dose titration.

DOI: 10.1016/j.pnpbp.2026.111645 Major depressive disorder Pharmacokinetics Depression economics Depressive symptoms +6

Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature

Journal of Psychopharmacology February 16, 2026 Marten Kase, Karl Kristjan Kaup, Jaan Aru 1 citation

We carried out a systematic review of modern-era (1990-2025) placebo-controlled studies assessing the acute and post-acute effects of lysergic acid diethylamide, dimethyltryptamine and psilocybin on cognitive and psychological functions. From February 28 to March 19, 2025, PubMed and APA PsychINFO were systematically searched for placebo-controlled studies examining the influence of...

DOI: 10.1177/02698811251412012 Psilocybin Cognition Hallucinogen Empathy +6

Cardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease.

Pharmacopsychiatry February 5, 2026 Tianyi Xu, Sabrina Wong, Gia Han Le et al.

Serotonergic psychedelics, such as lysergic acid diethylamide, and psilocybin, and the entactogen 3,4-methylenedioxymethamphetamine exhibit agonist activity at the 5-hydroxytryptamine 2B receptor, a signalling pathway known to mechanistically mediate drug-induced valvular heart disease. This systematic review evaluates whether chronic or repeated use of psychedelics and...

DOI: 10.1055/a-2794-6487 Full text

Psychedelic Symphonies: Investigating LSD and Music-Induced Brain Activity Using fMRI

February 3, 2026 Peter Moltke Skov-Andersen

LSD is a psychedelic drug known for its ability to alter perception and psychological functioning by acting on the serotonin 2A receptor. Historically, LSD and other psychedelics were used in psychiatry, and there is currently a resurgence of interest in their therapeutic potential. Recent studies suggest that psychedelic therapy, often involving the patient lying down with closed eyes and...

DOI: 10.31237/osf.io/xgh4w_v1 Parahippocampal gyrus Perception Active listening Cognitive psychology +8

Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland.

Psychiatry Research February 2, 2026 Tatiana Aboulafia Brakha, Albert Buchard, Cédric Mabilais et al. 1 citation

Classic serotonergic psychedelics such as LSD and psilocybin show promising antidepressant effects in controlled trials, but real-world data from routine clinical care remain limited. This study retrospectively analysed routine data from adults with treatment-resistant depressive and/or anxiety disorders who received a first standardized Psychedelic-assisted Psychotherapy (PAP) cycle with 100...

DOI: 10.1016/j.psychres.2026.116992 Full text Anxiety Depression LSD Mystical experience +2